Pfizer Unveils New End-To-End Digital Consumer Platform

PfizerForAll is a digital service designed to make getting medicines easier, and will be available to consumers for vaccines and migraine medicines. 

Pfizer is launching an end-to-end digital platform for some of its medicines and vaccines • Source: Shutterstock

Pfizer Inc. introduced the PfizerForAll platform with a goal of making some of its vaccines and medicines available to patients faster and more conveniently. The new digital platform, announced 27 August, is designed to make accessing medicines easier for consumers, starting with a few of the key disease areas Pfizer is involved in.

PfizerForAll will be available for patients with migraine, COVID-19 or flu and will be an option for patients seeking medicines for migraine or vaccines for COVID-19, respiratory syncytial virus (RSV) or pneumococcal pneumonia, the company said.

Pfizer markets the COVID-19 vaccine Comirnaty, the RSV vaccine Abrysvo, the pneumococcal vaccine Prevnar20 and the migraine medicines Nurtec ODT (rimegepant) and Zavzpret (zavegepant). However, the service won’t only provide Pfizer medicines and vaccines. “This isn’t just Pfizer’s treatments or vaccines. It is dependent on what the prescriber chooses for an individual,” the company told Scrip.

The timing of the launch coincides with the fall vaccination season and Pfizer hopes it will simplify the process for consumers.

“We once again face the threat of a possible tripledemic with influenza, RSV and COVID-19 co-circulating,” Pfizer told Scrip. “The growing number of approved vaccines, diagnostics and treatments to address respiratory illnesses is welcome news for society. However, this rapid pace of innovation has added complexity to the landscape for individuals, families and health care professionals.”

PfizerForAll works within the existing health care system, using a growing network of partners to simplify access.

Consumers can use their existing insurance and pharmacy programs on PfizerForAll, which is partnered with direct service companies UpScriptHealth, Alto Pharmacy and Instacart. The platform aims to solve some of the complexity in the US health care system and provide a new digital option for patients to manage their care.

PfizerForAll will provide access to same-day appointments with independent health care professionals, including both in-person and via telehealth, and it will provide home delivery of prescription medicines, over-the-counter treatments and diagnostic tests, or pick up at a preferred local pharmacy.

Another feature on the platform is scheduling for adult COVID-19, flu, RSV and pneumococcal pneumonia vaccinations. And, when it comes to paying for services or medications, PfizerForAll will have savings and support information in one place, with the goal of making it easier to find copay cards for eligible patients to access Pfizer’s support programs.

Pfizer is launching a multi-channel marketing campaign to make consumers and health care providers aware of the PfizerForAll platforms where they are most active.

“Our campaign is focused on reaching key audiences, including health care decision-makers who manage health and wellness decisions for themselves and their families, and those seeking support and looking to take key health actions related to our therapeutic areas of focus,” Pfizer said.

The company said it plans to expand and develop PfizerForAll, with the potential to address a broader range of needs and conditions.

More from Business

Aldeyra Expects Mid-2025 Refiling Of Reproxalap After Second CRL

 
• By 

Aldeyra’s dry eye candidate reproxalap received a second FDA complete response letter, but the firm expressed confidence about refiling quickly based on two ongoing studies.

Lilly Licenses Sangamo’s Capsid Technology For CNS Gene Therapy

 

Deal Snapshot: Lilly is the third company to sign a licensing deal for STAC-BBB with Sangamo, which also aims to secure a deal for its Fabry disease program in the second quarter.

Samsung Bioepis Reevaluating Approach To Biosimilars

 

The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.

Finance Watch: As Stocks Tumble, Offerings Slow, Financial Alternatives Rise

 
• By 

Public Company Edition: Stock valuations are falling due to political, economic and regulatory uncertainty, resulting in fewer large public offerings, more alternative financings and cost cuts. Carisma, Tenaya, BioAtla, Arbutus, Nkarta, Alector and Adaptimmune announced layoffs.

More from Scrip

Roche’s Brain Shuttle Delivers In Alzheimer’s, Moves Ahead To Phase III

 

By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.

Compass’ Bispecific BTC Contender Meets Phase II/III Endpoint

 
• By 

Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.

AZ’s Oncology R&D Head On China’s Scientific Promise And True Innovation

 

AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.